NCT07923253
Prospective Study of TVRFA Treatment for FIGO Type 3-5 Uterine Fibroids
StatusActive, Not Recruiting
PhaseNot applicable
SponsorUniversity of Novi Sad
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Percentage change in fibroid volume at 6 months after the intervention
Timeframe: 6 months after the procedure
Secondary (15)
Percentage change in fibroid volume at 1 month after the intervention
Percentage change in fibroid volume at 3 months after the intervention
Percentage change in fibroid volume at 12 months after the intervention
Change in uterine fibroid Symptom Severity Score (SSS)
Change in Overall Health-Related Quality of Life (HRQOL) Score
Show 10 moreShow less
Change in UFS-QOL Concern Domain Score
Change in UFS-QOL Activities Domain Score
Change in UFS-QOL Energy/Mood Domain Score
Change in UFS-QOL Control Domain Score
Change in UFS-QOL Self-Consciousness Domain Score
Change in UFS-QOL Sexual Function Domain Score
Incidence of Intraoperative and Postoperative Complications
Postoperative Pain Intensity
Duration of Postoperative Analgesic Use
Achievement of Pregnancy in Participants With Infertility
Arms and interventions
TVRFAM TreatmentExperimental
Participants with FIGO type 3-5 uterine fibroids measuring 2-10 cm undergo transvaginal radiofrequency ablation of myomas (TVRFAM). Up to three fibroids are treated during a single procedure. Participants are followed for 12 months to assess fibroid volume reduction, changes in quality of life, procedure-related pain, analgesic use, and complications or other adverse events.
Procedures: Radiofrequency ablation alone
Sites
1 site in 1 country
- Clinic for Gynecology and Obstetrics, University Clinical Center of Vojvodina, Novi Sad, SerbiaNovi Sad, Serbia